Pureims B.V.
Pure Inhalation Medication Systems (PureIMS) is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global Pharma companies, and with successful service providers. PureIMS’ lead candidate, Levodopa Cyclops, is in the final development stage as rescue therapy for OFF-episodes in Parkinson’s disease.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
One product, Colistin Cyclops™, is already marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. Some three other clinical programs – including Epinephrine Cyclops™ for impending (food) allergy induced anaphylaxis – are being explored in an early clinical stage. PureIMS also supports pharma/biotech partners, applying the Cyclops™-based inhalation route for their drug of choice.